Modern medicine is continually advancing treatment options for many chronic health conditions. For type 2 diabetes and obesity, GLP-1 receptor agonists are medications that may benefit your current ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 agonists and co-agonists conferred better ...
"This is the first GLP-1 receptor agonists study to show significant reduction in the risk of kidney failure…Our study establishes GLP-1 receptor agonists as an important kidney-protective class of ...
Glutamate levels increase in early psychosis but normalize over time, challenging established perspectives on schizophrenia progression. The study involved treatment-naive patients, isolating natural ...
Free fatty acid receptor 1 (FFAR1), also known as GPR40, has garnered significant interest as a therapeutic target in type 2 diabetes. Agonists of this receptor stimulate insulin secretion from ...
Morning Overview on MSN
Scientists watch drug molecules hit cell receptors in real time
Drug discovery is shifting from static snapshots to moving pictures. Instead of inferring how medicines work from end results ...
The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback